5 Best Immunology Stocks to Buy According to Hedge Funds

3. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 87

AbbVie Inc. (NYSE:ABBV) is among the best immunology stocks.

TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and fast-progressing blood cancer with limited available therapies. The authorization was supported by findings from the Phase 1/2 CADENZA study, which evaluated the treatment’s safety and clinical activity in BPDCN patients.

Trial results showed strong and lasting responses among newly diagnosed participants, including a 69.7% composite complete response rate and a median response duration of 9.7 months. Patients with relapsed or refractory disease recorded a 15.7% composite complete response rate with a 9.2-month median duration of response. Several patients later proceeded to stem cell transplantation following treatment.

Separately, on May 22, AbbVie Inc. (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a favorable recommendation for Maviret, the company’s oral pangenotypic antiviral therapy for acute hepatitis C. The recommendation covers treatment for adults as well as children aged 3 years and older. ABBV stated that a final decision from the European Commission is anticipated during the third quarter of 2026. If authorized, Maviret would become approved in the European Union for both acute and chronic hepatitis C infections, potentially expanding its treatment use across a broader patient population.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company and a leader in immunology. Spun off from Abbott Laboratories in 2013, it develops treatments for immune-mediated diseases across rheumatology, dermatology, and gastroenterology, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis.